XenoPort Announces Presentations of Data for Arbaclofen Placarbil and XP13512 at the Associated Professional Sleep Society Meeting
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jun 7, 2010 - XenoPort announced today that data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the Associated Professional Sleep Society meeting in San Antonio, Texas. The following data will be presented:
Arbaclofen placarbil, also known as XP19986
GERD
- Arbaclofen Placarbil Improves
Sleep Quality in Patients with Proton Pump Inhibitor (PPI) -
Responsive Gastroesophageal Reflux Disease (GERD)
Session: P15 Medical Disorders and Their Effects on Sleep: June 7, 2010, 10:30 a.m. - 12:30 p.m. CDT
Poster #: 270
XP13512 (gabapentin enacarbil)
Moderate-to-Severe Primary
Restless Legs Syndrome
- A Randomized, Crossover
Polysomnography Study of Gabapentin Enacarbil In Subjects with
Moderate-to-Severe Primary Restless Legs Syndrome and Associated
Sleep Disturbance
Oral Session: O15: Treatment Advances in Restless Legs Syndrome: June 8, 2010, 2:15 p.m. – 2:30 p.m. CDT
- Subjective Post-Sleep Diary
Findings from a Polysomnography Study of Gabapentin Enacarbil in
Subjects with Primary Restless Legs Syndrome and Associated Sleep
Disturbance
Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
Poster #: 261
- An Open-Label, 52-Week Extension
Study Assessing Tolerability and Efficacy of Gabapentin Enacarbil
in Subjects with Primary Restless Legs Syndrome
Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
Poster #: 262
- Population
Pharmacokinetic-Pharmacodynamic Relationship of Gabapentin after
Administration of Gabapentin Enacarbil in Subjects with Restless
Legs Syndrome
Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
Poster #: 263
- Effects of Gabapentin Enacarbil
on Quality of Life, Mood, and Function in Subjects with Restless
Legs Syndrome (RLS)
Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
Poster #: 264
- Gabapentin Enacarbil Maintains
Improvements in Sleep During Long-term Treatment in Subjects with
Moderate-to-Severe Primary Restless Legs Syndrome
Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
Poster #: 265
- An Evaluation of Restless Legs
Syndrome Symptom Augmentation in Subjects Treated with Gabapentin
Enacarbil for 12 weeks: Secondary Integrated Analyses from Two
Studies
Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
Poster #: 266
- Gabapentin Enacarbil Relieves
the Pain Associated with Restless Legs Syndrome (RLS)
Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
Poster #: 267
- Gabapentin Enacarbil Improves
Restless Legs Syndrome (RLS) Symptoms and Subjective Measures of
Sleep in Subjects With Primary RLS With and Without Severe Sleep
Disturbance: Secondary Analyses from Two Studies
Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. – 12:15 p.m. CDT
Poster #: 268
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. XenoPort's product candidates are being studied for the potential treatment of moderate-to-severe primary restless legs syndrome, neuropathic pain, migraine headaches, gastroesophageal reflux disease, spasticity and Parkinson's disease.
XenoPort is a registered trademark of XenoPort, Inc.
XNPT2C
Contact: XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
Posted: June 2010
